Expression of NY-ESO-1 in triple-negative breast cancer is associated with tumor-infiltrating lymphocytes and a good prognosis

Oncology (Switzerland)

Volumn 89, Issue 6, 2015, Pages 337-344

  Lee, Hee Jin ^a   Kim, Joo Young ^b   Song, In Hye ^a   Park, In Ah ^a   Yu, Jong Han ^a   Gong, Gyungyub ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b College of Medicine   (South Korea)

Author keywords

Immunotherapy; NY ESO 1; Prognosis; Triple negative breast cancer

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; NY ESO 1 ANTIGEN; PACLITAXEL; CTAG1B PROTEIN, HUMAN; MEMBRANE PROTEIN; TUMOR ANTIGEN; TUMOR MARKER;

ANTIGEN EXPRESSION; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL FEATURE; COHORT ANALYSIS; DISEASE FREE SURVIVAL; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; TISSUE MICROARRAY; TRIPLE NEGATIVE BREAST CANCER; TUMOR ASSOCIATED LEUKOCYTE; CANCER GRADING; CANCER STAGING; ENZYME IMMUNOASSAY; FEMALE; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TUMOR INVASION;

ANTIGENS, NEOPLASM; BIOMARKERS, TUMOR; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; LYMPHOCYTES, TUMOR-INFILTRATING; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84965091841     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000439535     Document Type: Article

References (41)

1. Ademuyiwa FO, Bshara W, Attwood K, Morrison C, Edge SB, Karpf AR, James SA, Ambrosone CB, O'Connor TL, Levine EG, Miliotto A, Ritter E, Ritter G, Gnjatic S, Odunsi K: NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer. PLoS One 2012; 7:e38783.
2. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA: Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res 2007; 13: 4429-4434.
3. Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C, Nagtegaal ID, Palmqvist R, Masucci GV, Botti G, Tatangelo F, Delrio P, Maio M, Laghi L, Grizzi F, Asslaber M, D'Arrigo C, Vidal-Vanaclocha F, Zavadova E, Chouchane L, Ohashi PS, Hafezi-Bakhtiari S, Wouters BG, Roehrl M, Nguyen L, Kawakami Y, Hazama S, Okuno K, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Wang Y, Kopetz S, Sinicrope FA, Scripcariu V, Ascierto PA, Marincola FM, Fox BA, Pages F: Towards the introduction of the 'immunoscore' in the classification of malignant tumours. J Pathol 2014; 232: 199-209.
4. Lee HJ, Song IH, Seo AN, Lim B, Kim JY, Lee JJ, Park IA, Shin J, Yu JH, Ahn JH, Gong G: Correlations between molecular subtypes and pathologic response patterns of breast cancers after neoadjuvant chemotherapy. Ann Surg Oncol 2015; 22: 392-400.
5. Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, Rouas G, Francis P, Crown JP, Hitre E, de Azambuja E, Quinaux E, Di Leo A, Michiels S, Piccart MJ, Sotiriou C: Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicinbased chemotherapy: BIG 02-98. J Clin Oncol 2013; 31: 860-867.
6. Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ, Wolff AC, Wood WC, Davidson NE, Sledge GW, Sparano JA, Badve SS: Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 2014; 32: 2959-2966.
7. Stagg J, Allard B: Immunotherapeutic approaches in triple-negative breast cancer: Latest research and clinical prospects. Ther Adv Med Oncol 2013; 5: 169-181.
8. Srivastava PK, Duan F: Harnessing the antigenic fingerprint of each individual cancer for immunotherapy of human cancer: Genomics shows a new way and its challenges. Cancer Immunol Immunother 2013; 62: 967-974.
9. Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca S, Franci C, Cheung TK, Fritsche J, Weinschenk T, Modrusan Z, Mellman I, Lill JR, Delamarre L: Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 2014; 515: 572-576.
10. Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Cliften P, Tycksen E, Samuels Y, Rosenberg SA: Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 2013; 19: 747-752.
11. Almeida LG, Sakabe NJ, deOliveira AR, Silva MC, Mundstein AS, Cohen T, Chen YT, Chua R, Gurung S, Gnjatic S, Jungbluth AA, Caballero OL, Bairoch A, Kiesler E, White SL, Simpson AJ, Old LJ, Camargo AA, Vasconcelos AT: CTdatabase: A knowledge-base of high-throughput and curated data on cancertestis antigens. Nucleic Acids Res 2009; 37:D816-D819.
12. Hofmann O, Caballero OL, Stevenson BJ, Chen YT, Cohen T, Chua R, Maher CA, Panji S, Schaefer U, Kruger A, Lehvaslaiho M, Carninci P, Hayashizaki Y, Jongeneel CV, Simpson AJ, Old LJ, Hide W: Genome-wide analysis of cancer/testis gene expression. Proc Natl Acad Sci USA 2008; 105: 20422-20427.
13. Chen YT, Ross DS, Chiu R, Zhou XK, Chen YY, Lee P, Hoda SA, Simpson AJ, Old LJ, Caballero O, Neville AM: Multiple cancer/testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancers. PLoS One 2011; 6:e17876.
14. Grigoriadis A, Caballero OL, Hoek KS, da Silva L, Chen YT, Shin SJ, Jungbluth AA, Miller LD, Clouston D, Cebon J, Old LJ, Lakhani SR, Simpson AJ, Neville AM: CT-X antigen expression in human breast cancer. Proc Natl Acad Sci USA 2009; 106: 13493-13498.
15. Hamai A, Duperrier-Amouriaux K, Pignon P, Raimbaud I, Memeo L, Colarossi C, Canzonieri V, Perin T, Classe JM, Campone M, Jezequel P, Campion L, Ayyoub M, Valmori D: Antibody responses to NY-ESO-1 in primary breast cancer identify a subtype target for immunotherapy. PLoS One 2011; 6:e21129.
16. Mischo A, Kubuschok B, Ertan K, Preuss KD, Romeike B, Regitz E, Schormann C, de Bruijn D, Wadle A, Neumann F, Schmidt W, Renner C, Pfreundschuh M: Prospective study on the expression of cancer testis genes and antibody responses in 100 consecutive patients with primary breast cancer. Int J Cancer 2006; 118: 696-703.
17. Goc J, Fridman WH, Sautes-Fridman C, Dieu-Nosjean MC: Characteristics of tertiary lymphoid structures in primary cancers. Oncoimmunology 2013; 2:e26836.
18. Rosen SD: Ligands for L-selectin: Homing, inflammation, and beyond. Annu Rev Immunol 2004; 22: 129-156.
19. Hanahan D, Weinberg RA: Hallmarks of cancer: The next generation. Cell 2011; 144: 646-674.
20. Bandic D, Juretic A, Sarcevic B, Separovic V, Kujundzic-Tiljak M, Hudolin T, Spagnoli GC, Covic D, Samija M: Expression and possible prognostic role of MAGE-A4, NYESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: Retrospective immunohistochemical study. Croat Med J 2006; 47: 32-41.
21. Sugita Y, Wada H, Fujita S, Nakata T, Sato S, Noguchi Y, Jungbluth AA, Yamaguchi M, Chen YT, Stockert E, Gnjatic S, Williamson B, Scanlan MJ, Ono T, Sakita I, Yasui M, Miyoshi Y, Tamaki Y, Matsuura N, Noguchi S, Old LJ, Nakayama E, Monden M: NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors. Cancer Res 2004; 64: 2199-2204.
22. Theurillat JP, Ingold F, Frei C, Zippelius A, Varga Z, Seifert B, Chen YT, Jager D, Knuth A, Moch H: NY-ESO-1 protein expression in primary breast carcinoma and metastases: Correlation with CD8 + T-cell and CD79a + plasmacytic/B-cell infiltration. Int J Cancer 2007; 120: 2411-2417.
23. Lakhani SR, Eilis IO, Schnitt SJ, Tan PH, Van de Vijver MJ (eds): WHO Classification of Tumours of the Breast, ed 4. Lyon, International Agency for Research on Cancer, 2012.
24. Lee HJ, Seo AN, Park SY, Kim JY, Park JY, Yu JH, Ahn JH, Gong G: Low prognostic implication of fibroblast growth factor family activation in triple-negative breast cancer subsets. Ann Surg Oncol 2014; 21: 1561-1568.
25. Hammond ME, Hayes DF, Wolff AC, Mangu PB, Temin S: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Oncol Pract 2010; 6: 195-197.
26. Harvey JM, Clark GM, Osborne CK, Allred DC: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17: 1474-1481.
27. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med 2014; 138: 241-256.
28. Jager E, Stockert E, Zidianakis Z, Chen YT, Karbach J, Jager D, Arand M, Ritter G, Old LJ, Knuth A: Humoral immune responses of cancer patients against 'cancer-testis' antigen NY-ESO-1: Correlation with clinical events. Int J Cancer 1999; 84: 506-510.
29. Davis ID, Chen W, Jackson H, Parente P, Shackleton M, Hopkins W, Chen Q, Dimopoulos N, Luke T, Murphy R, Scott AM, Maraskovsky E, McArthur G, MacGregor D, Sturrock S, Tai TY, Green S, Cuthbertson A, Maher D, Miloradovic L, Mitchell SV, Ritter G, Jungbluth AA, Chen YT, Gnjatic S, Hoffman EW, Old LJ, Cebon JS: Recombinant NY-ESO-1 protein with iscomatrix adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci USA 2004; 101: 10697-10702.
30. Jager E, Nagata Y, Gnjatic S, Wada H, Stockert E, Karbach J, Dunbar PR, Lee SY, Jungbluth A, Jager D, Arand M, Ritter G, Cerundolo V, Dupont B, Chen YT, Old LJ, Knuth A: Monitoring CD8 T cell responses to NY-ESO-1: Correlation of humoral and cellular immune responses. Proc Natl Acad Sci USA 2000; 97: 4760-4765.
31. Marchand M, Van Baren N, Weynants P, Brichard V, Dreno B, Tessier MH, Rankin E, Parmiani G, Arienti F, Humblet Y, Bourlond A, Vanwijck R, Lienard D, Beauduin M, Dietrich PY, Russo V, Kerger J, Masucci G, Jager E, De Greve J, Atzpodien J, Brasseur F, Coulie PG, Van Der Bruggen P, Boon T: Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999; 80: 219-230.
32. Sahin U, Tureci O, Chen YT, Seitz G, Villena-Heinsen C, Old LJ, Pfreundschuh M: Expression of multiple cancer/testis (CT) antigens in breast cancer and melanoma: Basis for polyvalent CT vaccine strategies. Int J Cancer 1998; 78: 387-389.
33. Mashino K, Sadanaga N, Tanaka F, Yamaguchi H, Nagashima H, Inoue H, Sugimachi K, Mori M: Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas. Br J Cancer 2001; 85: 713-720.
34. Curigliano G, Viale G, Ghioni M, Jungbluth AA, Bagnardi V, Spagnoli GC, Neville AM, Nole F, Rotmensz N, Goldhirsch A: Cancertestis antigen expression in triple-negative breast cancer. Ann Oncol 2011; 22: 98-103.
35. Grah JJ, Katalinic D, Juretic A, Santek F, Samarzija M: Clinical significance of immunohistochemical expression of cancer/testis tumor-associated antigens (MAGE-A1, MAGEA3/4, NY-ESO-1) in patients with non-small cell lung cancer. Tumori 2014; 100: 60-68.
36. Laban S, Atanackovic D, Luetkens T, Knecht R, Busch CJ, Freytag M, Spagnoli G, Ritter G, Hoffmann TK, Knuth A, Sauter G, Wilczak W, Blessmann M, Borgmann K, Muenscher A, Clauditz TS: Simultaneous cytoplasmic and nuclear protein expression of melanoma antigen-A family and NY-ESO-1 cancer-testis antigens represents an independent marker for poor survival in head and neck cancer. Int J Cancer 2014; 135: 1142-1152.
37. Sharma P, Shen Y, Wen S, Bajorin DF, Reuter VE, Old LJ, Jungbluth AA: Cancer-testis antigens: Expression and correlation with survival in human urothelial carcinoma. Clin Cancer Res 2006; 12: 5442-5447.
38. Gure AO, Chua R, Williamson B, Gonen M, Ferrera CA, Gnjatic S, Ritter G, Simpson AJ, Chen YT, Old LJ, Altorki NK: Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res 2005; 11: 8055-8062.
39. John T, Starmans MH, Chen YT, Russell PA, Barnett SA, White SC, Mitchell PL, Walkiewicz M, Azad A, Lambin P, Tsao MS, Deb S, Altorki N, Wright G, Knight S, Boutros PC, Cebon JS: The role of cancer-testis antigens as predictive and prognostic markers in nonsmall cell lung cancer. PLoS One 2013; 8:e67876.
40. Matkovic B, Juretic A, Spagnoli GC, Separovic V, Gamulin M, Separovic R, Saric N, Basic-Koretic M, Novosel I, Kruslin B: Expression of MAGE-A and NY-ESO-1 cancer/testis antigens in medullary breast cancer: Retrospective immunohistochemical study. Croat Med J 2011; 52: 171-177.
41. Gnjatic S, Atanackovic D, Jager E, Matsuo M, Selvakumar A, Altorki NK, Maki RG, Dupont B, Ritter G, Chen YT, Knuth A, Old LJ: Survey of naturally occurring CD4 + T cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responses. Proc Natl Acad Sci USA 2003; 100: 8862-8867.